文献速递妇科

林扎戈利与安慰剂治疗子宫内膜异位症相关疼痛:一项前瞻性、随机、双盲、3期研究(EDELWEISS 3)

Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).
PubMed 文献 · Hum Reprod · 2024-01-01

EDELWEISS 3是一项多中心、前瞻性、随机、安慰剂对照、双盲、双模拟3期研究,纳入486例子宫内膜异位症相关中重度疼痛患者,按1:1:1随机接受安慰剂、林扎戈利75 mg单药或林扎戈利200 mg联合反向添加治疗(ABT)。主要结果显示,200 mg联合ABT组在3个月时痛经和非经期盆腔痛应答率显著优于安慰剂,75 mg单药组仅痛经应答率显著优于安慰剂。

要点

  • 200 mg林扎戈利联合ABT在3个月时显著改善痛经和非经期盆腔痛,且镇痛药使用稳定或减少。
  • 75 mg林扎戈利单药在3个月时显著改善痛经,但对非经期盆腔痛的改善未达统计学显著。
  • 两种剂量组均观察到排便困难和整体盆腔痛的显著改善,性交痛改善未达显著。

核心结论

  • 林扎戈利200 mg联合ABT在治疗中重度子宫内膜异位症相关疼痛方面显示出优于安慰剂的疗效和安全性。
  • 75 mg单药可能适用于无需联合激素ABT的慢性治疗,但需进一步研究确认。

研究设计与样本

  • EDELWEISS 3为多中心、前瞻性、随机、安慰剂对照、双盲、双模拟3期研究,纳入486例子宫内膜异位症相关中重度疼痛受试者,按1:1:1随机分为安慰剂组、林扎戈利75 mg单药组或林扎戈利200 mg联合ABT组。
  • 治疗为口服每日一次,最长6个月;疼痛采用词语评定量表每日记录于电子日记。

主要发现

  • 3个月时,200 mg林扎戈利联合ABT组痛经应答率为72.9%,安慰剂组为23.5%(P < 0.001);非经期盆腔痛应答率分别为47.3%和30.9%(P = 0.007)。
  • 3个月时,75 mg林扎戈利组痛经应答率为44.0%,安慰剂组为23.5%(P < 0.001);非经期盆腔痛应答率组间比较P = 0.279,未达统计学显著。
  • 两林扎戈利组与安慰剂相比,排便困难和整体盆腔痛均显著改善;性交痛评分有小的改善但未达显著。
  • 两林扎戈利组低雌激素效应均轻微,潮热发生率和骨密度丢失率均低于1%。
  • 6个月治疗时,200 mg联合ABT或75 mg单药均显著减少痛经和非经期盆腔痛。

局限性

  • 疗效仅在林扎戈利组与安慰剂组间进行比较,与雌激素-孕激素或孕激素的对照研究结果将是有用的。
  • 需要确认促性腺激素释放激素拮抗剂是否较传统一线药物具有显著获益。
  • 75 mg单药用于慢性治疗的可能性需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does linzagolix administered orally once daily for up to 3 months at a dose of 75 mg alone or 200 mg in combination with add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethindrone acetate, also known as norethisterone acetate [NETA]) demonstrate better efficacy than placebo in the management of endometriosis-related dysmenorrhea and non-menstrual pelvic pain? SUMMARY ANSWER: Combining 200 mg linzagolix with ABT was found to significantly reduce dysmenorrhea and non-menstrual pelvic pain at 3 months of therapy, while a daily dose of 75 mg linzagolix yielded a significant decrease only in dysmenorrhea at 3 months. WHAT IS KNOWN ALREADY?: A previously published Phase 2, dose-finding study reported that at a dose of 200 mg daily, linzagolix promotes full suppression of estradiol secretion to serum levels below 20 pg/ml and noted that the addition of ABT may be needed to manage hypoestrogenic side effects. At lower doses (75 mg and 100 mg/day), linzagolix maintains estradiol values within the target range of 20-60 pg/ml, which could be ideal to alleviate symptoms linked to endometriosis. STUDY DESIGN, SIZE, DURATION: EDELWEISS 3 was a multicenter, prospective, randomized, placebo-controlled, double-blind, double-dummy Phase 3 study to evaluate the safety and efficacy of linzagolix for the treatment of moderate-to-severe endometriosis-associated pain. Treatment was administered orally once daily for up to 6 months. PARTICIPANTS/MATERIALS, SETTING, METHODS: In the EDELWEISS 3 trial, 486 subjects with moderate-to-severe endometriosis-associated pain were randomized at a 1:1:1 ratio to one of the three study groups: placebo, 75 mg linzagolix alone or 200 mg linzagolix in association with ABT. Pain was measured daily on a verbal rating scale and recorded in an electronic diary. MAIN RESULTS AND THE ROLE OF CHANCE: At 3 months, the daily 200 mg linzagolix dose with ABT met the primary efficacy objective, showing clinically meaningful and statistically significant reductions in dysmenorrhea and non-menstrual pelvic pain, with stable or decreased use of analgesics. The proportion of responders for dysmenorrhea in the 200 mg linzagolix with ABT group was 72.9% compared with 23.5% in the placebo group (P < 0.001), while the rates of responders for non-menstrual pelvic pain were 47.3% and 30.9% (P = 0.007), respectively. The 75 mg linzagolix daily dose demonstrated a clinically meaningful and statistically significant reduction in dysmenorrhea versus placebo at 3 months. The proportion of responders for dysmenorrhea in the 75 mg linzagolix group was 44.0% compared with 23.5% in the placebo group (P < 0.001). Although the 75 mg dose showed a trend toward reduction in non-menstrual pelvic pain at 3 months relative to the placebo, it was not statistically significant (P = 0.279). Significant improvements in dyschezia and overall pelvic pain were observed in both linzagolix groups when compared to placebo. Small improvements in dyspareunia scores were observed in both linzagolix groups but they were not significant. In both groups, hypoestrogenic effects were mild, with low rates of hot flushes and bone density loss of <1%. A daily dose of 200 mg linzagolix with ABT or 75 mg linzagolix alone was found to significantly reduce dysmenorrhea and non-menstrual pelvic pain also at 6 months of therapy. LIMITATIONS, REASONS FOR CAUTION: Efficacy was compared between linzagolix groups and placebo; however, it would be useful to have results from comparative studies with estro-progestogens or progestogens. It will be important to ascertain whether gonadotropin-releasing hormone antagonists have significant benefits over traditional first-line medications. WIDER IMPLICATIONS OF THE FINDINGS: Linzagolix administered orally once daily at a dose of 200 mg in combination with add-back therapy (ABT) demonstrated better efficacy and safety than placebo in the management of moderate-to-severe endometriosis-associated pain. The quality of life was improved and the risks of bone loss and vasomotor symptoms were minimized due to the ABT. The 75 mg dose alone could be suitable for chronic treatment of endometriosis-associated pain without the need for concomitant hormonal ABT, but further research is needed to confirm this. If confirmed, it would offer a viable option for women who do not want to wish to have ABT or for whom it is contraindicated. STUDY FUNDING/COMPETING INTEREST(S): Funding for the EDELWEISS 3 study was provided by ObsEva (Geneva, Switzerland). Analysis of data and manuscript writing were partially supported by ObsEva (Geneva, Switzerland), Theramex (London, UK) and Kissei (Japan) and grant 5/4/150/5 was awarded to M.-M.D. by FNRS. J.D. was a member of the scientific advisory board of ObsEva until August 2022, a member of the scientific advisory board of PregLem, and received personal fees from Gedeon Richter, ObsEva and Theramex. J.D. received consulting fees, speakers' fees, and travel support from Gedeon Richter, Obseva and Theramex, which was paid to their institution. C.B. has received fees from Theramex, Gedeon Richter, and Myovant, and travel support from Gedeon Richter-all funds went to the University of Oxford. He was a member of the data monitoring board supervising the current study, and served at an advisory board for endometriosis studies of Myovant. H.T. has received grants from Abbvie and was past president of ASRM. F.C.H. has received fees from Gedeon Richter and Theramex. O.D. received fees for lectures from Gedeon Richter and ObsEva and research grants for clinical studies from Preglem and ObsEva independent from the current study. A.H. has received grants from NIHR, UKRI, CSO, Wellbeing of Women, and Roche Diagnostics; he has received fees from Theramex. A.H.'s institution has received honoraria for consultancy from Roche Diagnostics, Gesynta, and Joii. M.P. has nothing to declare. F.P. has received fees from Theramex. S.P.R. has been a member of the scientific advisory board of Gedeon Richter and received fees from Gedeon Richter. A.P. and M.B. are employees of Theramex. E.B. was an employee of ObsEva, sponsor chair of the data monitoring board supervising the current study, and has been working as a consultant for Theramex since December 2022; she owns stock options in ObsEva. M.-M.D. has received fees and travel support from Gedeon Richter and Theramex. TRIAL REGISTRATION NUMBER: NCT03992846. TRIAL REGISTRATION DATE: 20 June 2019. DATE OF FIRST PATIENT’S ENROLLMENT: 13 June 2019.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Donnez J, Becker C, Taylor H, et al. Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3). Hum Reprod. 2024. PMID: 38648863. doi:10.1093/humrep/deae076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。